Logo image of TBPH

THERAVANCE BIOPHARMA INC (TBPH) Stock Fundamental Analysis

NASDAQ:TBPH - Nasdaq - KYG8807B1068 - Common Stock - Currency: USD

9.315  -0.35 (-3.57%)

After market: 9.315 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to TBPH. TBPH was compared to 193 industry peers in the Pharmaceuticals industry. TBPH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TBPH is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TBPH has reported negative net income.
TBPH had a negative operating cash flow in the past year.
TBPH had negative earnings in 4 of the past 5 years.
In the past 5 years TBPH always reported negative operating cash flow.
TBPH Yearly Net Income VS EBIT VS OCF VS FCFTBPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M 600M 800M

1.2 Ratios

TBPH's Return On Assets of -13.87% is fine compared to the rest of the industry. TBPH outperforms 67.57% of its industry peers.
TBPH's Return On Equity of -26.61% is fine compared to the rest of the industry. TBPH outperforms 68.11% of its industry peers.
Industry RankSector Rank
ROA -13.87%
ROE -26.61%
ROIC N/A
ROA(3y)25.31%
ROA(5y)-8.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TBPH Yearly ROA, ROE, ROICTBPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TBPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TBPH Yearly Profit, Operating, Gross MarginsTBPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1K -1K

More info and screens

5

2. Health

2.1 Basic Checks

TBPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TBPH has less shares outstanding
The number of shares outstanding for TBPH has been reduced compared to 5 years ago.
TBPH has a worse debt/assets ratio than last year.
TBPH Yearly Shares OutstandingTBPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
TBPH Yearly Total Debt VS Total AssetsTBPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

TBPH has an Altman-Z score of -2.00. This is a bad value and indicates that TBPH is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -2.00, TBPH perfoms like the industry average, outperforming 43.78% of the companies in the same industry.
TBPH has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
TBPH has a Debt to Equity ratio (0.16) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Altman-Z -2
ROIC/WACCN/A
WACC9.72%
TBPH Yearly LT Debt VS Equity VS FCFTBPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 4.97 indicates that TBPH has no problem at all paying its short term obligations.
The Current ratio of TBPH (4.97) is better than 65.41% of its industry peers.
TBPH has a Quick Ratio of 4.97. This indicates that TBPH is financially healthy and has no problem in meeting its short term obligations.
TBPH has a better Quick ratio (4.97) than 67.03% of its industry peers.
Industry RankSector Rank
Current Ratio 4.97
Quick Ratio 4.97
TBPH Yearly Current Assets VS Current LiabilitesTBPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

TBPH shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
The Revenue has grown by 16.16% in the past year. This is quite good.
TBPH shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.01% yearly.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.94%
Revenue 1Y (TTM)16.16%
Revenue growth 3Y-7.22%
Revenue growth 5Y-1.01%
Sales Q2Q%7.49%

3.2 Future

Based on estimates for the next years, TBPH will show a very strong growth in Earnings Per Share. The EPS will grow by 29.82% on average per year.
The Revenue is expected to grow by 24.72% on average over the next years. This is a very strong growth
EPS Next Y-11.46%
EPS Next 2Y45.32%
EPS Next 3Y23.97%
EPS Next 5Y29.82%
Revenue Next Year9%
Revenue Next 2Y22.36%
Revenue Next 3Y19.74%
Revenue Next 5Y24.72%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TBPH Yearly Revenue VS EstimatesTBPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
TBPH Yearly EPS VS EstimatesTBPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TBPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 85.95, TBPH can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, TBPH is valued a bit cheaper than 72.97% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.70, TBPH is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 85.95
TBPH Price Earnings VS Forward Price EarningsTBPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TBPH Per share dataTBPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as TBPH's earnings are expected to grow with 23.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y45.32%
EPS Next 3Y23.97%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TBPH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THERAVANCE BIOPHARMA INC

NASDAQ:TBPH (2/21/2025, 8:00:01 PM)

After market: 9.315 0 (0%)

9.315

-0.35 (-3.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)02-26 2025-02-26/amc
Inst Owners94.28%
Inst Owner Change-98%
Ins Owners5.82%
Ins Owner Change-0.77%
Market Cap458.02M
Analysts80
Price Target14.03 (50.62%)
Short Float %8.66%
Short Ratio21.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-21.64%
Min EPS beat(2)-32.93%
Max EPS beat(2)-10.35%
EPS beat(4)1
Avg EPS beat(4)-12.01%
Min EPS beat(4)-32.93%
Max EPS beat(4)7.36%
EPS beat(8)3
Avg EPS beat(8)-10.35%
EPS beat(12)3
Avg EPS beat(12)-33.93%
EPS beat(16)6
Avg EPS beat(16)-23.42%
Revenue beat(2)1
Avg Revenue beat(2)-0.89%
Min Revenue beat(2)-9.55%
Max Revenue beat(2)7.78%
Revenue beat(4)2
Avg Revenue beat(4)-0.64%
Min Revenue beat(4)-9.55%
Max Revenue beat(4)7.78%
Revenue beat(8)3
Avg Revenue beat(8)-5.89%
Revenue beat(12)5
Avg Revenue beat(12)-4.83%
Revenue beat(16)5
Avg Revenue beat(16)-7.31%
PT rev (1m)4.17%
PT rev (3m)4.17%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3600%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.5%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-36.08%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 85.95
P/S 7.25
P/FCF N/A
P/OCF N/A
P/B 2.47
P/tB 2.47
EV/EBITDA N/A
EPS(TTM)-0.95
EYN/A
EPS(NY)0.11
Fwd EY1.16%
FCF(TTM)-0.25
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS1.29
BVpS3.78
TBVpS3.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.87%
ROE -26.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)25.31%
ROA(5y)-8.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.27%
Cap/Sales 1.3%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.97
Quick Ratio 4.97
Altman-Z -2
F-Score4
WACC9.72%
ROIC/WACCN/A
Cap/Depr(3y)37.82%
Cap/Depr(5y)52.04%
Cap/Sales(3y)3.87%
Cap/Sales(5y)5.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.94%
EPS Next Y-11.46%
EPS Next 2Y45.32%
EPS Next 3Y23.97%
EPS Next 5Y29.82%
Revenue 1Y (TTM)16.16%
Revenue growth 3Y-7.22%
Revenue growth 5Y-1.01%
Sales Q2Q%7.49%
Revenue Next Year9%
Revenue Next 2Y22.36%
Revenue Next 3Y19.74%
Revenue Next 5Y24.72%
EBIT growth 1Y37.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year80.01%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y88.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y89.1%
OCF growth 3YN/A
OCF growth 5YN/A